Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$11.25M$11.25M+127.9% vs Q2 2019 Net Income-$4.95M-$4.95MN/M vs Q2 2019 EPS Diluted-$0.09-$0.09N/M vs Q2 2019 Operating Income-$4,655,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,839,000N/M Margins · derivedOperating margin-41.4%+206.5 pt vs Q2 2019
Net margin-44.0%+194.3 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end